Demystifying Medicine Video

A clinical trial in the United States is looking to cure a type of genetic blindness called Leber congenital amaurosis (LCA) with the use of CRISPR technology.

More information on this clinical trial:

Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10

[Please complete our feedback form]


Accessibility for Ontarians With Disabilities Act (AODA)


The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at